The most recent Neurocrine Biosciences (NBIX) insider transaction: Ingrid Delaet (Chief Regulatory Officer) received 4,483 shares as a grant or award on Sep 11, 2026, reported on Form 4 on Sep 15, 2026. So far in the quarter ending Dec 31, 2026, insider holdings showed no net buying or selling.
In the last 12 months, insiders at Neurocrine Biosciences made open-market sales of $77.87 million (501.95K shares) and bought no shares on the open market.
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Kevin Charles Gorman | Chief Executive Officer | 517,797 | 0 | 517,797 | 41.7% | 15 Sep, 2026 |
| 2 | Kyle Gano | Chief Executive Officer | 154,728 | 0 | 154,728 | 12.5% | 15 Sep, 2026 |
| 3 | Gary A Lyons | President And Ceo | 122,141 | 0 | 122,141 | 9.8% | 21 May, 2026 |
| 4 | Eric Benevich | Chief Commercial Officer | 67,297 | 0 | 67,297 | 5.4% | 15 Sep, 2026 |
| 5 | Darin Lippoldt | Chief Legal Officer | 56,793 | 0 | 56,793 | 4.6% | 15 Sep, 2026 |
| 6 | William H Rastetter | Director | 43,678 | 0 | 43,678 | 3.5% | 21 May, 2026 |
| 7 | Matt Abernethy | Chief Financial Officer | 42,808 | 0 | 42,808 | 3.4% | 15 Sep, 2026 |
| 8 | Malcolm Lloyd-Smith | Chief Integration Officer | 42,337 | 0 | 42,337 | 3.4% | 08 Feb, 2023 |
| 9 | Richard F Pops | Director | 37,798 | 0 | 37,798 | 3.0% | 21 May, 2026 |
| 10 | Eiry Roberts | Chief Medical Officer | 35,640 | 0 | 35,640 | 2.9% | 14 Feb, 2025 |
| 11 | Julie Cooke | Chief Human Resources Officer | 24,025 | 0 | 24,025 | 1.9% | 15 Sep, 2026 |
| 12 | Jude Onyia | Chief Scientific Officer | 22,647 | 0 | 22,647 | 1.8% | 15 Sep, 2026 |
| 13 | Ingrid Delaet | Chief Regulatory Officer | 18,289 | 0 | 18,289 | 1.5% | 15 Sep, 2026 |
| 14 | Stephen A Sherwin | Director | 14,860 | 0 | 14,860 | 1.2% | 03 Sep, 2026 |
| 15 | George J Morrow | Director | 10,386 | 0 | 10,386 | 0.8% | 21 May, 2026 |
| 16 | David W. Boyer | Chief Corp. Affairs Officer | 8,722 | 0 | 8,722 | 0.7% | 15 Sep, 2026 |
| 17 | Johanna Mercier | Director | 6,853 | 0 | 6,853 | 0.6% | 21 May, 2026 |
| 18 | Christine A Poon | Director | 4,753 | 0 | 4,753 | 0.4% | 21 May, 2026 |
| 19 | Shalini Sharp | Director | 4,088 | 0 | 4,088 | 0.3% | 21 May, 2026 |
| 20 | Sanjay Chandru Keswani | Chief Medical Officer | 3,281 | 0 | 3,281 | 0.3% | 15 Sep, 2026 |
| 21 | Leslie V Norwalk | Director | 2,430 | 0 | 2,430 | 0.2% | 30 Jul, 2026 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 11 Sep, 2026 | Ingrid Delaet | Chief Regulatory Officer | Acquired A | 4,483 | $0.00 | $0 | 20,708 | Direct |
| 11 Sep, 2026 | Julie Cooke | Chief Human Resources Officer | Acquired A | 3,587 | $0.00 | $0 | 25,961 | Direct |
| 11 Sep, 2026 | Sanjay Chandru Keswani | Chief Medical Officer | Acquired A | 3,914 | $0.00 | $0 | 5,393 | Direct |
| 11 Sep, 2026 | Eric Benevich | Chief Commercial Officer | Acquired A | 6,275 | $0.00 | $0 | 70,683 | Direct |
| 11 Sep, 2026 | Matt Abernethy | Chief Financial Officer | Acquired A | 5,020 | $0.00 | $0 | 47,828 | Direct |
| 11 Sep, 2026 | Kyle Gano | Chief Executive Officer | Acquired A | 6,275 | $0.00 | $0 | 157,266 | Direct |
| 11 Sep, 2026 | Jude Onyia | Chief Scientific Officer | Acquired A | 3,587 | $0.00 | $0 | 24,583 | Direct |
| 11 Sep, 2026 | David W. Boyer | Chief Corp. Affairs Officer | Acquired A | 3,587 | $0.00 | $0 | 11,484 | Direct |
| 11 Sep, 2026 | Kevin Charles Gorman | Director | Acquired A | 14,343 | $0.00 | $0 | 525,636 | Direct |
| 11 Sep, 2026 | Darin Lippoldt | Chief Legal Officer | Acquired A | 4,483 | $0.00 | $0 | 59,212 | Direct |
| 11 Sep, 2026 | David W. Boyer | Chief Corp. Affairs Officer | Disposed F | 1,936 | $156.22 | $302.44K | 9,548 | Direct |
| 11 Sep, 2026 | Darin Lippoldt | Chief Legal Officer | Disposed F | 2,419 | $156.22 | $377.90K | 56,793 | Direct |
| 11 Sep, 2026 | Ingrid Delaet | Chief Regulatory Officer | Disposed F | 2,419 | $156.22 | $377.90K | 18,289 | Direct |
| 11 Sep, 2026 | Kyle Gano | Chief Executive Officer | Disposed F | 3,386 | $156.22 | $528.96K | 153,880 | Direct |
| 11 Sep, 2026 | Sanjay Chandru Keswani | Chief Medical Officer | Disposed F | 2,112 | $156.22 | $329.94K | 3,281 | Direct |
| 11 Sep, 2026 | Kevin Charles Gorman | Director | Disposed F | 7,839 | $156.22 | $1.22Mn | 517,797 | Direct |
| 11 Sep, 2026 | Eric Benevich | Chief Commercial Officer | Disposed F | 3,386 | $156.22 | $528.96K | 67,297 | Direct |
| 11 Sep, 2026 | Matt Abernethy | Chief Financial Officer | Disposed F | 2,709 | $156.22 | $423.20K | 45,119 | Direct |
| 11 Sep, 2026 | Julie Cooke | Chief Human Resources Officer | Disposed F | 1,936 | $156.22 | $302.44K | 24,025 | Direct |
| 11 Sep, 2026 | Jude Onyia | Chief Scientific Officer | Disposed F | 1,936 | $156.22 | $302.44K | 22,647 | Direct |